Fungal infection-related mortality versus total mortality as an outcome in trials of antifungal agents by Due, Anne K et al.
BioMed  Central
Page 1 of 6
(page number not for citation purposes)
BMC Medical Research 
Methodology
Open Access Research article
Fungal infection-related mortality versus total mortality as an 
outcome in trials of antifungal agents
Anne K Due†, Helle K Johansen and Peter C Gøtzsche*†
Address: Nordic Cochrane Centre, Rigshospitalet, Dept. 7112, Blegdamsvej 9, DK-2100 København Ø, Denmark
Email: Anne K Due - anne.k.due@sol.dk; Helle K Johansen - hkj@cochrane.dk; Peter C Gøtzsche* - pcg@cochrane.dk
* Corresponding author    †Equal contributors
Abstract
Background: Disease specific mortality is often used as outcome rather than total mortality in
clinical trials. This approach assumes that the classification of cause of death is unbiased. We
explored whether use of fungal infection-related mortality as outcome rather than total mortality
leads to bias in trials of antifungal agents in cancer patients.
Methods: As an estimate of bias we used relative risk of death in those patients the authors
considered had not died from fungal infection. Our sample consisted of 69 trials included in four
systematic reviews of prophylactic or empirical antifungal treatment in patients with cancer and
neutropenia we have published previously.
Results: Thirty trials met the inclusion criteria. The trials comprised 6130 patients and 869 deaths,
220 (25%) of which were ascribed to fungal infection. The relative risk of death was 0.85 (95% CI
0.75–0.96) for total mortality, 0.57 (95% CI 0.44–0.74) for fungal mortality, and 0.95 (95% CI 0.82–
1.09) for mortality among those who did not die from fungal infection.
Conclusion:  We could not support the hypothesis that use of disease specific mortality
introduces bias in antifungal trials on cancer patients as our estimate of the relative risk for
mortality in those who survived the fungal infection was not increased. We conclude that it seems
to be reliable to use fungal mortality as the primary outcome in trials of antifungal agents. Data on
total mortality should be reported as well, however, to guard against the possible introduction of
harmful treatments.
Background
Disease specific mortality is often used as outcome rather
than total mortality in clinical trials. This approach
assumes that the classification of cause of death is unbi-
ased. However, a comparison of noncancer death rates in
cancer patients with noncancer death rates in a matched
population showed that use of cancer specific mortality
may underestimate the mortality related to cancer, and
that treatment-related deaths seemed to have been omit-
ted from cancer mortality [1]. A review of cancer screening
trials also identified inconsistencies between disease spe-
cific mortality and all-cause mortality [2], and it has been
shown that biased misclassification of cause of death can
give a spurious advantage to aggressive cancer treatments
over less aggressive treatments [3].
For antifungal agents, a higher incidence of bacterial
infections has been reported which might be a class effect
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related to the azole drugs [4], and itraconazole is associ-
ated with congestive heart failure [5]. As aggressive treat-
ment may increase mortality due to treatment but
decrease mortality due to the disease in question, bias in
classification of cause of death may influence the results
of the trials. According to the recommendations of the
CONSORT Group all deaths should be reported regardless
of cause [6].
In this study we explored whether use of fungal infection-
related mortality as outcome rather than total mortality
leads to bias in trials of antifungal agents in cancer
patients. Most patients with invasive fungal infection are
suffering from severe underlying conditions [7], and as
fungal infections are difficult to diagnose, misclassifica-
tion of cause of death may occur. Accordingly, in autopsy
studies many patients were considered to have died from
a fungal infection that was not suspected or confirmed
antemortem [8].
Methods
We used a sample consisting of trials included in 4 sys-
tematic reviews concerning prophylactic or empirical
treatment in patients with cancer and neutropenia at risk
for fungal infections, which we have published previously
[4,9-11]. According to our protocol, trials had to be ran-
domised, published as full papers, include mainly cancer
patients and report on at least one fungal death and one
death from another cause to be included in the study.
Details on overall mortality and disease specific mortality
were extracted by two persons independently and disa-
greements were resolved by discussion. Data were ana-
lysed as relative risks [12] and 95% confidence intervals
(CI) are presented. A fixed effect model was used since
there was very little heterogeneity between the studies.
As an estimate of bias we used relative risk of death in
those patients the authors considered had not died from
fungal infection. Provided the two groups are still compa-
rable after subtraction of fungal deaths from those ran-
domised, the proportion of those who died from another
cause than fungal infection would be expected to be the
same in the two groups (fig. 1a). If, however, there was a
bias in classification of cause of death in favour of the
treated group, fewer deaths would be ascribed to fungal
infection and more deaths to other causes in this group.
This would result in a larger relative risk of death for those
who did not die from fungal infection (fig. 1b).
Relative risk of death from causes other than fungal infection in those who survived the fungal infection Figure 1
Relative risk of death from causes other than fungal infection in those who survived the fungal infection. Pro-
vided the two groups are still comparable after subtraction of fungal deaths from those randomised, the proportion of those 
who died from another cause than fungal infection would be expected to be the same in the two groups (fig. 1a). If, however, 
there was a bias in classification of cause of death in favour of the treated group, fewer deaths would be ascribed to fungal 
infection and more deaths to other causes in this group. This would result in a larger relative risk of death for those who did 
not die from fungal infection (fig. 1b). This risk is an estimate of bias overall: RR = (dexp/(Nexp-Fexp))/(dctr/(Nctr-Fctr)), where exp: 
experimental group; ctr: control group; Nexp, Nctr: numbers of randomised patients; Fexp, Fctr: numbers of deaths from fungal 
infection; dexp, dctr: numbers of deaths from causes other than fungal infection.
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Results
Our sample consisted of 69 trials [13-81] 30 of which met
the inclusion criteria [13-42]. Thirty-one trials were
excluded as they did not report the necessary mortality
data, 4 were published as abstracts and in 4 trials the
patients did not have cancer. The interventions were no
treatment, placebo, amphotericin B, fluconazole, micona-
zole, itraconazole and nystatin. In all trials that compared
two drugs, it was easy to decide which was the experimen-
tal one and which was the control drug.
The trials comprised 6130 patients and 869 deaths, 220
(25%) of which were ascribed to fungal infection. The rel-
ative risk of death was 0.85 (95% CI 0.75–0.96) for total
mortality, 0.57 (95% CI 0.44–0.74) for fungal mortality,
and 0.95 (95% CI 0.82–1.09) for mortality among those
who did not die from fungal infection (see additional files
1, 2, 3 for graphs and data extracted from the studies).
Discussion
We could not support the hypothesis that use of disease
specific mortality introduces bias in antifungal trials on
cancer patients as our estimate of the relative risk for mor-
tality in those who survived the fungal infection was not
increased. We had expected some increase, even in the
absence of any misclassification bias, since, in case of pos-
itive treatment effects, more severely ill patients would
survive in the experimental group which would be
expected to increase their risk of death, compared with
surviving patients in the control group. It should be
noted, however, that the confidence interval for our risk
estimate, 0.82–1.09, is compatible with the possible exist-
ence of minor bias.
Subgroup analyses should generally be discouraged when
a null hypothesis of no difference (no bias in our case)
could not be rejected. However, we did an exploratory
analysis where we included only those trials that were not
blinded since the risk of bias is largest in these trials. The
total number of deaths among those who survived the
fungal infection was 255, as compared with 649 for the
corresponding analysis for all the trials. The relative mor-
tality risk among those who did not die from fungal infec-
tion was 0.90 (95% CI 0.72–1.14), which is very similar
to our estimate of 0.95 (95% CI 0.82–1.09) for all the tri-
als.
Conclusion
We conclude that it seems to be reliable to use fungal mor-
tality as the primary outcome in trials of antifungal agents.
Data on total mortality should be reported as well, how-
ever, to guard against the possible introduction of harm-
ful treatments as we cannot know whether our findings
will apply to future antifungal agents.
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